Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas - PubMed (original) (raw)
. 2016 Dec;69(12):1046-1050.
doi: 10.1136/jclinpath-2015-203588. Epub 2016 May 11.
Affiliations
- PMID: 27169755
- DOI: 10.1136/jclinpath-2015-203588
Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas
Christopher J Kim et al. J Clin Pathol. 2016 Dec.
Abstract
Aims: Special AT-rich sequence-binding protein 2 (SATB2) is a novel immunomarker that is expressed in glandular cells of the lower gastrointestinal tract with retained expression in the majority of primary and metastatic colorectal adenocarcinomas (CRCs). Because of its tissue specificity, SATB2 has been shown to be a clinically useful marker to distinguish CRC from non-CRC. In this study, we investigated whether or not SATB2 can help differentiate CRC from small intestinal adenocarcinoma (SIA), a practical diagnostic challenge due to their morphological and immunophenotypic similarities.
Methods: Fifty surgically resected primary SIAs and 50 CRCs were immunohistochemically examined for the expression of SATB2. Positive staining was graded as 1+ (5-25% of the tumour cells stained), 2+ (26-50%), 3+ (51-75%) or 4+ (>75%), as well as weak, intermediate or strong for staining intensity.
Results: Positive SATB2 immunoreactivity was observed in 23 (46%) SIAs in contrast to 48 (96%) CRCs (p<0.0001). Among these, only 4 (8%) SIAs showed strong and diffuse (4+) SATB2 staining compared with 38 (76%) of CRCs (p<0.0001).
Conclusions: SATB2 is not entirely CRC-specific and is expressed in a subset of SIAs. Unlike CRC, however, SIA infrequently shows a strong and diffuse staining pattern, which still makes SATB2 a useful immunomarker to distinguish SIA from CRC.
Keywords: COLORECTAL CANCER; IMMUNOCYTOCHEMISTRY; SMALL INTESTINE.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Similar articles
- SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY. Zhang YJ, et al. EBioMedicine. 2018 Feb;28:62-69. doi: 10.1016/j.ebiom.2018.01.001. Epub 2018 Jan 9. EBioMedicine. 2018. PMID: 29396302 Free PMC article. - SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas.
Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A, Wester K, Gry M, Bjartell A, Gallagher WM, Rexhepaj E, Kilpinen S, Kallioniemi OP, Belt E, Goos J, Meijer G, Birgisson H, Glimelius B, Borrebaeck CA, Navani S, Uhlén M, O'Connor DP, Jirström K, Pontén F. Magnusson K, et al. Am J Surg Pathol. 2011 Jul;35(7):937-48. doi: 10.1097/PAS.0b013e31821c3dae. Am J Surg Pathol. 2011. PMID: 21677534 - The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A, Sar A, Laco J, Metelkova A, Miesbauerova M, Steiner P, Švajdler M, Michal M. Skalova A, et al. Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):140-146. doi: 10.1097/PAI.0000000000000388. Appl Immunohistochem Mol Morphol. 2018. PMID: 27258560 - SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
Berg KB, Schaeffer DF. Berg KB, et al. Arch Pathol Lab Med. 2017 Oct;141(10):1428-1433. doi: 10.5858/arpa.2016-0243-RS. Arch Pathol Lab Med. 2017. PMID: 28968158 Review. - SATB1 and 2 in colorectal cancer.
Brocato J, Costa M. Brocato J, et al. Carcinogenesis. 2015 Feb;36(2):186-91. doi: 10.1093/carcin/bgu322. Epub 2014 Dec 27. Carcinogenesis. 2015. PMID: 25543122 Free PMC article. Review.
Cited by
- SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendations.
Zarate YA, Fish JL. Zarate YA, et al. Am J Med Genet A. 2017 Feb;173(2):327-337. doi: 10.1002/ajmg.a.38022. Epub 2016 Oct 24. Am J Med Genet A. 2017. PMID: 27774744 Free PMC article. Review. - SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY. Zhang YJ, et al. EBioMedicine. 2018 Feb;28:62-69. doi: 10.1016/j.ebiom.2018.01.001. Epub 2018 Jan 9. EBioMedicine. 2018. PMID: 29396302 Free PMC article. - Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall.
Neri G, Arpa G, Guerini C, Grillo F, Lenti MV, Giuffrida P, Furlan D, Sessa F, Quaquarini E, Viglio A, Ubezio C, Pasini A, Ferrero S, Sampietro G, Ardizzone S, Latella G, Mescoli C, Rugge M, Zingone F, Barresi V, Ciccocioppo R, Pedrazzoli P, Corazza GR, Luinetti O, Solcia E, Paulli M, Di Sabatino A, Vanoli A. Neri G, et al. Cancers (Basel). 2020 Nov 19;12(11):3441. doi: 10.3390/cancers12113441. Cancers (Basel). 2020. PMID: 33228145 Free PMC article. - American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies.
Bellizzi AM, Montgomery EA, Hornick JL. Bellizzi AM, et al. Ann Diagn Pathol. 2020 Feb;44:151419. doi: 10.1016/j.anndiagpath.2019.151419. Epub 2019 Nov 15. Ann Diagn Pathol. 2020. PMID: 31786484 Free PMC article. Review. - Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report.
Matsuo M, Hatano Y, Imaizumi Y, Kuroda T, Arai T, Tomita H, Matsuhashi N, Yoshida K, Hara A. Matsuo M, et al. Diagn Pathol. 2020 Aug 31;15(1):106. doi: 10.1186/s13000-020-01019-6. Diagn Pathol. 2020. PMID: 32867793 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical